ProstaLund (Sweden) Today
| PLUN Stock | SEK 9.00 2.00 28.57% |
Performance0 of 100
| Odds Of DistressOver 63
|
ProstaLund is selling for under 9.00 as of the 26th of December 2024; that is 28.57 percent increase since the beginning of the trading day. The stock's last reported lowest price was 7.0. ProstaLund has more than 63 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. ProstaLund has reported 40 for 1 split on 23rd of December 2024. The performance scores are derived for the period starting the 26th of November 2024 and ending today, the 26th of December 2024. Click here to learn more.
ProstaLund AB develops, manufactures, and sells urological devices and treatments. The company has 57.19 M outstanding shares. More on ProstaLund AB
Moving against ProstaLund Stock
ProstaLund Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. ProstaLund's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding ProstaLund or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Medical Care Facilities, Healthcare (View all Sectors) |
ProstaLund AB (PLUN) is traded on Stockholm Exchange in Sweden and employs 7 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 248.19 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate ProstaLund's market, we take the total number of its shares issued and multiply it by ProstaLund's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. ProstaLund AB operates under Healthcare sector and is part of Medical Care Facilities industry. The entity has 57.19 M outstanding shares.
ProstaLund AB has accumulated about 19.11 M in cash with (5.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.98.
Check ProstaLund Probability Of Bankruptcy
Ownership AllocationProstaLund owns a total of 57.19 Million outstanding shares. ProstaLund has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check ProstaLund Ownership Details
ProstaLund AB Risk Profiles
Although ProstaLund's alpha and beta are two of the key measurements used to evaluate ProstaLund's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.4 | |||
| Standard Deviation | 5.16 | |||
| Variance | 26.63 | |||
| Risk Adjusted Performance | (0.1) |
ProstaLund Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in ProstaLund without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Premium Stories Now
Premium StoriesFollow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
| All Next | Launch Module |
ProstaLund Corporate Management
Elected by the shareholders, the ProstaLund's board of directors comprises two types of representatives: ProstaLund inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ProstaLund. The board's role is to monitor ProstaLund's management team and ensure that shareholders' interests are well served. ProstaLund's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ProstaLund's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Erika Carlsson | Chief Officer | Profile | |
| Charlotta Andersson | Sales Finland | Profile | |
| Goran Dybner | Marketing Director | Profile | |
| Leo Gurvich | Chief Marked | Profile | |
| Johan Wennerholm | Chief Officer | Profile |
Additional Tools for ProstaLund Stock Analysis
When running ProstaLund's price analysis, check to measure ProstaLund's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProstaLund is operating at the current time. Most of ProstaLund's value examination focuses on studying past and present price action to predict the probability of ProstaLund's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProstaLund's price. Additionally, you may evaluate how the addition of ProstaLund to your portfolios can decrease your overall portfolio volatility.